181 related articles for article (PubMed ID: 20712799)
1. Treatment options for thalassemia patients with osteoporosis.
Terpos E; Voskaridou E
Ann N Y Acad Sci; 2010 Aug; 1202():237-43. PubMed ID: 20712799
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis and management of osteoporosis in thalassemia.
Voskaridou E; Terpos E
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():86-93. PubMed ID: 19337161
[TBL] [Abstract][Full Text] [Related]
3. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia.
Voskaridou E; Terpos E
Br J Haematol; 2004 Oct; 127(2):127-39. PubMed ID: 15461618
[TBL] [Abstract][Full Text] [Related]
4. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
[TBL] [Abstract][Full Text] [Related]
5. Role of iron in osteoporosis.
Weinberg ED
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():81-5. PubMed ID: 19337160
[TBL] [Abstract][Full Text] [Related]
6. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates in the treatment of thalassemia-associated osteoporosis.
Gaudio A; Morabito N; Xourafa A; Macrì I; Meo A; Morgante S; Trifiletti A; Lasco A; Frisina N
J Endocrinol Invest; 2008 Feb; 31(2):181-4. PubMed ID: 18362512
[TBL] [Abstract][Full Text] [Related]
8. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
Voskaridou E; Christoulas D; Antoniadou L; Terpos E
Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
[No Abstract] [Full Text] [Related]
9. What is new in the treatment of steroid-induced osteoporosis?
Liu RH; Werth VP
Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
[TBL] [Abstract][Full Text] [Related]
10. The spine in β-thalassemia syndromes.
Haidar R; Mhaidli H; Musallam KM; Taher AT
Spine (Phila Pa 1976); 2012 Feb; 37(4):334-9. PubMed ID: 21494197
[TBL] [Abstract][Full Text] [Related]
11. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
[TBL] [Abstract][Full Text] [Related]
12. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
[TBL] [Abstract][Full Text] [Related]
13. Drug insight: Existing and emerging therapies for osteoporosis.
Mulder JE; Kolatkar NS; LeBoff MS
Nat Clin Pract Endocrinol Metab; 2006 Dec; 2(12):670-80. PubMed ID: 17143314
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis.
Otrock ZK; Mahfouz RA; Charafeddine KM; Rayes RF; Zahed LF; Taher AT
Ann Hematol; 2008 Nov; 87(11):947-8. PubMed ID: 18443790
[No Abstract] [Full Text] [Related]
15. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
16. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
[TBL] [Abstract][Full Text] [Related]
17. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment.
Chatterjee R; Bajoria R
Hemoglobin; 2009; 33 Suppl 1():S136-8. PubMed ID: 20001617
[TBL] [Abstract][Full Text] [Related]
18. [Idiopathic and secondary osteoporosis in childhood].
Rossi F; Perrotta S; Falcone E; Gimigliano F; Iodice M; Vetrella S; Iolascon G
Minerva Pediatr; 2005 Oct; 57(5):203-11. PubMed ID: 16205605
[TBL] [Abstract][Full Text] [Related]
19. Oral iron chelators.
Kwiatkowski JL
Hematol Oncol Clin North Am; 2010 Feb; 24(1):229-48. PubMed ID: 20113905
[TBL] [Abstract][Full Text] [Related]
20. Assessment and treatment of cardiac iron overload in thalassemia.
Aessopos A; Farmakis D; Andreopoulos A; Tsironi M
Hemoglobin; 2009; 33 Suppl 1():S87-92. PubMed ID: 20001638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
